197 Serum interleukin-2 levels in the first 24–72 hours post CD19 CAR T cell infusion is a robust biomarker of CAR T cell expansion in leukemia and lymphoma patients treated with Axi-cel or Brexu-celChad M. Williams, Davide Bedognetti, Justin A. Budka et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0
In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 TranscriptSoumya Poddar, Mike Mattie, Justin A. Budka et al.|Blood|2024Cited by 0
Abstract 3194: Opposing roles of product CD27 and TIGIT expression in outcome to CAR-T cell therapy in R/R LBCLJustin A. Budka, Simone Filosto, Subing Cao et al.|Cancer Research|2025Cited by 0
Genomic correlates of clinical CAR T cell activityMark B. Leick, Marcela V. Maus, Filippo Birocchi et al.|Science Immunology|2026Cited by 0
266 Functional and genomics analysis on product identifies key features driving resistance to CAR T-cell therapy, including dysfunctional GATA3+ CD8 T cellsSoumya Poddar, Davide Bedognetti, Gabriela Balderrama-Gutierrez et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0